Conclusion:
Tocilizumab administration in subjects with severe COVID-19 infection
reduced the mortality rate in all time points, however, the incidence of
adverse effect was higher. Therefore, patients with severe COVID-19
specially those with hyperinflammation may benefit from tocilizumab use
taking into consideration the adverse effects of the biological drug.
However, the limitations of the study would encourage researchers to
conduct further investigations with randomized clinical trials.
Ethics Statement: The authors confirm that the ethical policies
of the journal, as noted on the journal’s author guidelines page, have
been adhered to. No ethical approval was required as this is a review
article with no original research data